Hypobaric Exposure

SECTION TWO

Human Performance in Extreme Environments

CHAPTER 9 | HYPOBARIC EXPOSURE

The Atmosphere, Gas Laws, Chronic Hypoxia, Acclimatization, DCS & Trapped Gas Disorders — CAsP Unit 9 Objectives 1–48

Hypobaric exposure — exposure to environments of reduced barometric pressure — is the defining physiological challenge of aviation and high-altitude operations. As an aviator ascends from sea level, the atmosphere thins, oxygen partial pressure falls, gas-filled body cavities expand, and dissolved nitrogen begins to supersaturate tissues. The consequences span from the insidious onset of hypoxia to the explosive pain of decompression sickness to the locked-door agony of an unequalized ear block. This chapter provides the foundational knowledge that differentiates aerospace medicine from all other medical specialties: a precise, quantitative understanding of how the human body responds to the most fundamental hazard of the aviation environment — the loss of atmospheric pressure.

This chapter follows the exact CAsP Unit 9 objective structure across 48 objectives organized into five major sections: the atmosphere and gas laws (Objectives 9.1–9.11), chronic hypoxia and acclimatization (9.12–9.32), bubble formation and decompression sickness (9.13, 9.36–9.43), and trapped gas disorders of the ear and sinuses (9.44–9.48).

SECTION A: THE ATMOSPHERE AND GAS LAWS

The atmosphere is the physical medium through which aircraft fly and against which all of aviation physiology is defined. Understanding its composition, pressure structure, temperature divisions, and standard day values is the baseline from which every hypobaric physiological calculation proceeds.

The Earth’s atmosphere is a mixture of gases held to the planet by gravity. Its composition by volume in the dry (water-vapor-free) lower atmosphere is remarkably constant from the surface to approximately 80–85 km (homosphere):

Table 9.1. Composition of the Dry Atmosphere at Sea Level

The physiologically critical fractions are oxygen (21%) and nitrogen (79%, used here as the combined inert gas fraction including argon). Water vapor partial pressure varies with temperature and humidity; in body temperature alveolar gas, PH₂O = 47 mmHg regardless of altitude — a constant that must be subtracted from barometric pressure in all alveolar gas calculations.

Atmospheric pressure is the weight of the column of air above a unit area of the Earth’s surface. It equals the sum of the partial pressures of all atmospheric gases at that altitude. Atmospheric pressure decreases exponentially with altitude because there is progressively less overlying atmosphere above any given point. The decrease is approximately:

• ~1 mmHg per 30 ft (10 m) ascent at sea level altitudes.
• Exponential rather than linear — pressure halves for every 18,000 ft increase in altitude (roughly), so the rate of decrease slows at very high altitudes.
• At sea level: ~760 mmHg (standard). At 18,000 ft: ~380 mmHg (half of sea level). At 63,000 ft (Armstrong’s Line): ~47 mmHg — equal to water vapor pressure at body temperature.

The U.S. Standard Atmosphere (also International Standard Atmosphere, ISA) defines a model atmosphere used for aircraft performance calculations, altimeter calibration, and physiological planning:

• Sea-level pressure: 29.92 in Hg = 760 mmHg = 1013.25 hPa (mb) = 14.696 psi = 1 atmosphere (ATA).
• Sea-level temperature: 59°F = 15°C = 288.15 K.
• Sea-level air density: 0.002377 slugs/ft³.
• Temperature lapse rate in the troposphere: Standard lapse rate = 3.5°F (1.98°C) per 1,000 ft = ~2°C/1,000 ft. Used for all standard day calculations.

Table 9.2. Standard Units of Atmospheric Pressure and Sea Level Values

The standard lapse rate in the troposphere is 2°C per 1,000 ft (approximately 6.5°C per 1,000 m). The formula:

• T(altitude) = T(sea level) − (Lapse Rate × Altitude in thousands of ft)
• T(altitude) = 15°C − (2°C × altitude/1,000 ft)

Worked examples:

• At 10,000 ft: T = 15 − (2 × 10) = 15 − 20 = −25°C... [Correction: T = 15 − 20 = −5°C]
• At 25,000 ft: T = 15 − (2 × 25) = 15 − 50 = −35°C
• At 36,000 ft (tropopause): T = 15 − (2 × 36) = 15 − 72 = −57°C ≈ −56.5°C (ISA tropopause)

Above the tropopause (~36,000 ft / 11 km), temperature becomes constant at −56.5°C in the lower stratosphere (isothermal layer) — the standard lapse rate does not apply above the tropopause.

Table 9.3. Physiological Divisions of the Atmosphere

Table 9.4. Temperature Divisions of the Atmosphere

SECTION B: GAS LAWS

Boyle’s Law: At constant temperature, the volume of a fixed mass of gas varies inversely with its absolute pressure.

• Formula: P₁V₁ = P₂V₂ (constant temperature, constant amount of gas)
• Equivalently: V₂ = (P₁ × V₁) / P₂

Calculation examples relevant to aviation physiology:

• Example 1 — Ear block on ascent: Middle ear gas volume = 1 mL at sea level (760 mmHg). Pilot ascends to 18,000 ft (380 mmHg). New volume = (760 × 1) / 380 = 2 mL. Middle ear gas doubles in volume. If Eustachian tube is blocked, this causes barotrauma.
• Example 2 — DCS bubble on descent: A bubble forms at 25,000 ft (282 mmHg) with volume of 1 cm³. Pilot descends to sea level (760 mmHg). New volume = (282 × 1) / 760 = 0.37 cm³. Descent compresses bubble to 37% of its altitude volume — the therapeutic mechanism of recompression.
• Example 3 — GI gas expansion: Intestinal gas volume at sea level (760 mmHg) = 100 mL. At 18,000 ft (380 mmHg): V = (760 × 100) / 380 = 200 mL. Volume doubles, causing discomfort.

Charles’ Law: At constant pressure, the volume of a fixed mass of gas varies directly with its absolute temperature.

• Formula: V₁/T₁ = V₂/T₂ (constant pressure; temperature in KELVIN: K = °C + 273)
• Equivalently: V₂ = V₁ × (T₂ / T₁)

Example: A gas sample of 1 L at 37°C (310 K) is cooled to −35°C (238 K, the approximate temperature at 25,000 ft). Assuming constant pressure:

• V₂ = 1.0 × (238/310) = 0.768 L. The volume decreases by about 23% due to temperature decrease alone.

In aviation physiology, Charles’ Law is less clinically dominant than Boyle’s Law because body temperature is tightly regulated and does not change significantly with altitude. However, it is important for understanding gas volume changes in non-body systems (e.g., oxygen bottles, inflation systems) exposed to extreme altitude temperatures. The combined effect of pressure AND temperature changes on gas volume is described by the General (Ideal) Gas Law: P₁V₁/T₁ = P₂V₂/T₂.

Henry’s Law: The amount of gas dissolved in a liquid at a given temperature is directly proportional to the partial pressure of that gas in contact with the liquid.

• Formula: C = k × P(gas), where C = concentration of dissolved gas, k = solubility coefficient (tissue-specific), P = partial pressure of gas.

Aviation physiology applications:

• Sea-level tissue N₂ loading: At sea level, tissue P(N₂) ≈ 573 mmHg (Dalton’s Law: 760 − 47 − 40 − 100 = 573 mmHg). All body tissues are saturated with nitrogen at this partial pressure by Henry’s Law.
• Ascent and supersaturation: At 18,000 ft (P(N₂) in inspired air ≈ 300 mmHg), tissue nitrogen is now in excess of the new equilibrium value. Henry’s Law predicts nitrogen will leave solution. If the rate of off-gassing exceeds elimination capacity, bubbles form (DCS).
• Denitrogenation (O₂ prebreathe): Breathing 100% O₂ sets inspired P(N₂) = 0. By Henry’s Law, the maximum gradient from tissue to alveolus is established, maximizing nitrogen elimination rate.

Dalton’s Law: The total pressure of a mixture of gases equals the sum of the partial pressures of each component gas. Each component gas exerts the same pressure it would exert if it occupied the space alone.

• Formula: P(total) = P(N₂) + P(O₂) + P(CO₂) + P(H₂O) + P(other gases)
• Partial pressure of any gas: P(gas) = P(total) × F(gas), where F = fractional concentration (0 to 1.0)

Calculation examples:

• Alveolar O₂ at sea level: PB = 760 mmHg. PAO₂ = PB − PH₂O − PACO₂ − PN₂ = 760 − 47 − 40 − 573 = 100 mmHg.
• P(O₂) at 18,000 ft (PB = 380 mmHg) breathing air: P(O₂) = 380 × 0.2095 = 79.6 mmHg inspired. Alveolar: ≈380 − 47 − 40 − 236 ≈ 57 mmHg. Severe hypoxia.
• P(O₂) at 25,000 ft (PB = 282 mmHg) breathing air: Inspired P(O₂) = 282 × 0.2095 = 59 mmHg. Alveolar ≈ 35 mmHg. Life-threatening hypoxia without O₂ supplementation.
• P(N₂) at sea level: 760 × 0.79 ≈ 600 mmHg inspired; 573 mmHg alveolar (after subtracting water vapor, O₂, CO₂ at equilibrium).

SECTION C: CHRONIC HYPOXIA AND ACCLIMATIZATION (Objectives 9.12–9.32)

Altitude acclimatization is the complex of adaptive physiological responses that improve tolerance to sustained hypobaric hypoxia. These responses occur over different time scales and involve multiple organ systems, with the common goal of protecting tissues against hypoxic stress. The key processes are summarized below:

Table 9.5. Phases of Altitude Acclimatization

The oxygen-hemoglobin dissociation curve (ODC) relates PaO₂ to hemoglobin saturation (SaO₂%). The sigmoid shape of the ODC has critical implications for altitude physiology:

• Flat upper portion (PaO₂ 60–100 mmHg): SaO₂ remains 90–98%. Moderate altitude hypoxia (up to approximately 10,000–12,000 ft breathing air) causes relatively small falls in SaO₂.
• Steep lower portion (PaO₂ <60 mmHg): Small falls in PaO₂ cause large falls in SaO₂. Above ~18,000 ft breathing air, SaO₂ falls steeply into the range of severe hypoxia.

Table 9.6. Altitude, Alveolar PO₂, and Approximate Hemoglobin Saturation Breathing Air

Acute hypoxia stimulates increased ventilation (hypoxic ventilatory response, HVR) primarily through the peripheral chemoreceptors. The ventilatory response has two stages with opposing effects on alveolar CO₂:

• Carotid body (peripheral chemoreceptor) detection of falling PaO₂ → ↑ afferent signals to the brainstem respiratory centers → ↑ tidal volume and respiratory rate → ↑ alveolar ventilation.
• Increased alveolar ventilation → more CO₂ exhaled per minute → PACO₂ falls (hypocapnia) and PaO₂ rises (toward the inspired level as ventilation increases).
• Hypocapnia (low PACO₂) causes respiratory alkalosis (pH rises). This alkalosis inhibits the central chemoreceptors (which respond to CO₂/pH) and partially brakes the ventilatory drive, creating a ventilatory compromise between hypoxic stimulation (driving ventilation up) and hypocapnic inhibition (partially restraining it).

Net alveolar gas effect of hyperventilation at altitude:

• PAO₂ rises (beneficial — partially compensates for reduced inspired PO₂).
• PACO₂ falls (below 40 mmHg → respiratory alkalosis; causes hypocapnic vasoconstriction, paresthesias).

The carotid bodies are small chemoreceptor organs located bilaterally at the bifurcation of the common carotid arteries. They are the primary sensors of arterial PO₂ in the acute hypoxic ventilatory response:

• Sensing: Specialized glomus (Type I) cells within the carotid body are exquisitely sensitive to reductions in PaO₂. They respond to PaO₂ not SaO₂ — they begin increasing their firing rate below approximately 60–70 mmHg PaO₂ (in the steep portion of the ODC).
• Signal transmission: Glomus cells release dopamine and other neurotransmitters that activate the carotid sinus nerve (branch of CN IX, glossopharyngeal) → nucleus tractus solitarius in the medulla → activation of inspiratory premotor neurons → ↑ phrenic nerve output → ↑ diaphragm activity → ↑ tidal volume and rate.
• Threshold: The hypoxic ventilatory response is hyperbolic: minimal response above PaO₂ = 60 mmHg; steep response below this. This means ventilation does not increase significantly during mild hypoxia (compatible with the flat upper portion of the ODC), but increases dramatically with severe hypoxia.
• Bilateral carotid body ablation or disease: Loss of peripheral chemoreceptor function eliminates the acute hypoxic ventilatory response. Such individuals do not increase ventilation during hypoxia and are at extreme risk at altitude — a relevant aeromedical consideration for aircrew with carotid artery disease or prior endarterectomy.

The immediate adaptive responses to acute altitude exposure represent the body’s first-line defenses against hypobaric hypoxia. They develop within minutes to hours:

• Increased ventilation (HVR): As described in 9.15–9.16. Raises PAO₂ by reducing alveolar CO₂ and ventilating more efficiently. The most rapid compensation.
• Increased heart rate and cardiac output: Sympathetic activation in response to hypoxia and carotid body input raises HR and contractility, increasing O₂ delivery to tissues. HR typically increases 20–40% at 14,000–18,000 ft without acclimatization.
• Cerebral vasodilation: Local hypoxia directly dilates cerebral vessels, increasing cerebral blood flow and maintaining cerebral O₂ delivery despite reduced arterial O₂ content. This partially compensates for reduced PaO₂ but also contributes to altitude headache.
• Pulmonary vasoconstriction (HPV): Hypoxic pulmonary vasoconstriction redirects blood flow from poorly ventilated (hypoxic) alveoli toward better-ventilated regions, reducing V/Q mismatch and improving gas exchange efficiency. Chronic HPV can lead to pulmonary hypertension at high altitude.
• Shift of ODC (right): Initially modest; more significant with chronic acclimatization. 2,3-DPG rises over 24–48 hours, reducing O₂-Hb affinity and facilitating O₂ unloading to tissues.

Altitude-induced hyperventilation is a double-edged adaptation: it raises PAO₂ (beneficial) but also lowers PACO₂ (creating respiratory alkalosis with multiple effects):

• Respiratory alkalosis: PACO₂ below 40 mmHg → arterial pH rises above 7.40 → respiratory alkalosis. This partially inhibits the central chemoreceptors, providing a brake on further ventilation increase.
• Cerebral vasoconstriction: Hypocapnia causes cerebral arteriolar constriction, reducing cerebral blood flow. This partially counteracts the direct hypoxic cerebral vasodilation and may worsen cerebral O₂ delivery despite increased systemic PaO₂.
• Paresthesias: Respiratory alkalosis increases protein binding of ionized Ca²⁺ (reduced free Ca²⁺) → increased neuronal excitability → tingling in the extremities and perioral region (the classic symptoms of hyperventilation also seen in altitude exposure).
• Left shift of ODC: Alkalosis increases O₂-Hb affinity (Bohr effect) → O₂ loads better in lungs (beneficial) but unloads less readily in tissues (potentially harmful at the tissue level during acute hypoxia). Over 24–48 hours, rising 2,3-DPG shifts the ODC back to the right.

Acute altitude exposure produces a characteristic cardiovascular response:

• Submaximal heart rate: INCREASES significantly at any given absolute workload. At 14,000–18,000 ft without acclimatization, HR at a given submaximal exercise intensity may be 20–40 bpm above sea-level values for the same absolute work. This reflects sympathetic activation from hypoxia and the need to increase cardiac output to compensate for reduced arterial O₂ content.
• Resting heart rate: Also increases, reflecting sympathetic activation from carotid body input even at rest.
• Cardiac output: Increases acutely (both HR and stroke volume rise initially). Over the first few days at altitude, plasma volume falls (acute diuresis from respiratory alkalosis), reducing preload; cardiac output may normalize or even fall slightly despite persistent tachycardia.
• Maximum cardiac output: Decreases with increasing altitude because maximal HR is constrained (the heart rate cannot exceed physiological limits) and stroke volume is limited by reduced preload (plasma volume loss). This is a key mechanism of reduced VO₂max at altitude.

The most important chronic acclimatization response for increasing O₂ carrying capacity is erythropoiesis — the production of new red blood cells:

• Hypoxia stimulates the kidney (and to a lesser extent the liver) to produce erythropoietin (EPO) within 2–4 hours of hypoxic exposure.
• EPO acts on erythroid progenitor cells in bone marrow, stimulating red cell production.
• Reticulocyte count rises within 2–4 days; hemoglobin concentration begins rising within the first week.
• Full polycythemic response requires 3–6 weeks. Hemoglobin may reach 18–22 g/dL in high-altitude residents (vs. ~14–16 g/dL at sea level).
• Total blood oxygen carrying capacity increases (more hemoglobin per liter of blood → more O₂ per liter).

However, very high hemoglobin concentrations increase blood viscosity, which increases vascular resistance and cardiac work, and predisposes to thrombosis. This is the pathological extreme seen in Chronic Mountain Sickness (Monge’s disease).

• Acid-base adjustment: Initial respiratory alkalosis (from hyperventilation) is partially compensated by renal bicarbonate excretion over 2–3 days. Arterial pH returns toward (but does not fully reach) 7.40. This compensation removes the hypocapnic brake, allowing further increase in ventilation, which further raises PAO₂ — a key positive loop in acclimatization.
• Plasma volume: Acutely DECREASES within the first 24–48 hours at altitude due to increased respiratory water loss (breathing cold, dry altitude air increases insensible loss), diuresis from aldosterone suppression (driven by respiratory alkalosis), and fluid shifts. A 10–15% plasma volume reduction is common in the first days. This initially CONCENTRATES red cells, producing a pseudo-polycythemia (hematocrit rises despite no new RBC production).
• Red cell mass: TRUE polycythemia (EPO-driven increase in total circulating red blood cells) develops over 3–6 weeks. This is the adaptive increase in O₂ carrying capacity critical for long-term altitude tolerance. Total red cell mass may increase 30–50% in fully acclimatized individuals.

Table 9.7. Time-Course of Altitude Acclimatization Responses

VO₂max (maximal oxygen uptake, the gold standard measure of aerobic capacity) decreases progressively and predictably with increasing altitude above approximately 1,500 m (5,000 ft):

• Rate of decline: Approximately 1% per 100 m (approximately 330 ft) above 1,500 m. At 3,000 m (approximately 10,000 ft), VO₂max is approximately 15% below sea level. At 5,500 m (approximately 18,000 ft), it is approximately 40–50% below sea level. At extreme altitude (8,000 m), VO₂max may be near resting O₂ consumption.
• Mechanism: The primary factor is reduced arterial O₂ content (CaO₂ = SaO₂ × Hb × 1.34 + PaO₂ × 0.003). As PaO₂ falls with altitude, SaO₂ falls (especially below 60 mmHg on the steep ODC), reducing CaO₂. Maximum O₂ delivery to muscles = CO(max) × CaO₂, and with reduced CaO₂, maximum O₂ delivery falls even if CO(max) is maintained.
• Altitude acclimatization effect: Acclimatization partially restores VO₂max (through polycythemia and other adaptations) but never fully returns it to sea level values at the same altitude — the reduced PO₂ remains the ceiling.

Whether altitude acclimatization / training improves VO₂max upon return to sea level has been extensively studied in the context of altitude training for athletic performance:

• The ‘live high, train low’ (LHTL) strategy: Living at altitude (inducing polycythemia and other acclimatization adaptations) while training at lower altitude (where training intensity is preserved) has been shown to improve sea-level VO₂max and endurance performance in elite athletes.
• Return to sea level performance window: The performance benefit is greatest in the first 2–3 weeks after descent from altitude (while polycythemia is still elevated). Benefits dissipate within 2–3 weeks as EPO falls and extra red cells are destroyed.
• Effect on non-elite/patient populations: Acclimatization benefits for sea-level VO₂max are less consistently demonstrated in non-elite populations and depend heavily on altitude, duration, and individual response.

Extended altitude stays (weeks to months) produce the most complete acclimatization responses but also introduce performance trade-offs:

• Extended stay benefits: Full polycythemia (3–6 weeks), complete acid-base compensation, increased capillary density, mitochondrial density, and enzyme adaptations. The fully acclimatized individual performs better at altitude than a newcomer.
• Training quality trade-off: High-intensity training at altitude is limited because VO₂max is reduced — the athlete cannot train at the same absolute intensity as at sea level. This limits training stimulus for speed and power. Low-altitude training intervals (even brief descents) preserve the high-intensity training stimulus.
• Optimal protocol: Modern altitude training programs use LHTL: sleep and rest at altitude (e.g., 2,500–3,000 m) for acclimatization stimulus; travel to low altitude (or use a low-hypoxic tent) for high-intensity workouts.

These three altitude illness syndromes represent a clinical spectrum of maladaptation to hypobaric hypoxia, ranging from the common and self-limited to the rare and life-threatening:

• Acute Mountain Sickness (AMS): The most common altitude illness syndrome, characterized by headache plus at least one of: nausea/vomiting, fatigue/weakness, dizziness/lightheadedness, or difficulty sleeping — occurring within 6–12 hours of ascent to altitude above approximately 2,500 m (8,200 ft) in unacclimatized individuals. The headache is generally the cardinal symptom. AMS is defined by the Lake Louise Score (≥3 with headache required).
• High Altitude Pulmonary Edema (HAPE): A non-cardiogenic pulmonary edema occurring above approximately 2,500–3,500 m (8,200–11,500 ft), typically 2–4 days after ascent. Results from exaggerated hypoxic pulmonary vasoconstriction with inhomogeneous blood flow causing elevated capillary pressure in non-constricted regions, leading to fluid leakage into the alveolar space. The leading cause of death from high-altitude illness.
• High-Altitude Cerebral Edema (HACE): The most severe end of the altitude illness spectrum. Cerebral vasogenic edema with progressive brain swelling. Typically develops from untreated severe AMS. Presents as severe headache progressing to ataxia (cerebellar dysfunction), altered consciousness, and eventually coma. Requires immediate descent and treatment.

• Required: Headache (cardinal symptom; typically bifrontal, worsened by bending forward or Valsalva).
• Plus ≥1: Nausea and/or vomiting; fatigue and/or weakness; dizziness and/or lightheadedness; difficulty sleeping (poor sleep quality, frequent awakenings, Cheyne-Stokes respiration at altitude).
• Severity (Lake Louise Score): Mild AMS = score 3–4; Moderate = 5–6; Severe = ≥7 (approaching HACE territory).

Prophylaxis

• Staged ascent: Most effective non-pharmacological prevention. Ascend no more than 300–500 m (1,000–1,640 ft) per day above 2,500 m; rest day every 3rd day of ascent.
• Acetazolamide (Diamox): Carbonic anhydrase inhibitor. Inhibits renal HCO₃⁻ reabsorption → metabolic acidosis → stimulates ventilation (compensatory hyperventilation) → ↑ PAO₂ → reduces AMS risk. Dose: 125–250 mg BID starting 24 hours before ascent. Side effects: polyuria, paresthesias (from diuresis), taste alteration (carbonated beverages). Contraindicated: sulfonamide allergy.
• Dexamethasone: Corticosteroid. Reduces cerebral vasogenic edema and improves symptoms. Used for prevention when acclimatization time is unavailable (e.g., emergency operations) or treatment of severe AMS. Dose: 4 mg q6h. Does NOT accelerate acclimatization — masks symptoms.

Treatment

• Halt ascent; rest at current altitude until symptoms resolve (mild AMS).
• Descend if symptoms worsen or do not improve within 24 hours.
• Supplemental oxygen (increases PAO₂, reduces hypoxic stimulus).
• Acetazolamide 250 mg BID (accelerates acclimatization).
• Dexamethasone 4 mg q6h (for severe AMS or rapid symptom relief).
• Portable hyperbaric bag (Gamow bag, Certec bag): Pressurizes patient to simulate descent; effective when actual descent is not possible.

HAPE typically develops 2–4 days after rapid ascent above 2,500–3,500 m (8,200–11,500 ft). Symptoms progress through characteristic stages:

• Early: Decreased exercise tolerance (first and most reliable early symptom); dry cough; dyspnea on exertion greater than expected for altitude; mild cyanosis.
• Moderate: Dyspnea at rest; productive cough (initially white or pink frothy sputum); cyanosis at rest; bilateral crackles on auscultation.
• Severe: Severe dyspnea; frank pulmonary edema with pink frothy sputum; central cyanosis; altered consciousness (due to hypoxemia); cardiovascular compromise.

Prophylaxis

• Staged ascent: Primary prevention. Slower ascent allows HPV to distribute more uniformly.
• Nifedipine: Calcium channel blocker. Reduces pulmonary artery pressure by reducing HPV. For high-risk individuals (prior HAPE history): 30 mg extended-release daily starting 1 day before ascent.
• Salmeterol: Beta-2 agonist. Accelerates alveolar fluid clearance (reduces HAPE risk ~50% in HAPE-susceptible individuals).
• Acetazolamide: Some evidence for HAPE prevention through improved ventilation.

Treatment

• Immediate descent: Most important and most effective intervention. Even 300–500 m (1,000–1,640 ft) descent dramatically improves HAPE.
• Supplemental oxygen (high flow; 4–8 L/min) — reduces HPV and improves oxygenation.
• Nifedipine 10 mg sublingual or 30 mg extended-release oral (reduces pulmonary artery pressure).
• Portable hyperbaric bag (Gamow bag) if descent impossible.
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): Reduce pulmonary artery pressure; adjunct to descent.

HACE typically develops after AMS has been present, representing progression to cerebral vasogenic edema with brain swelling:

• Severe headache: Unresponsive to standard analgesics; often the worst headache the patient has experienced.
• Ataxia (truncal): The most reliable early sign of HACE. Cannot perform tandem gait (heel-to-toe walk in a straight line). This is the critical sign that separates HACE from severe AMS.
• Altered mental status: Confusion, disorientation, hallucinations, behavioral changes.
• Coma: Terminal stage without treatment.

Prophylaxis

• Staged ascent (primary prevention). Treat AMS before it progresses to HACE.
• Acetazolamide (stimulates ventilation, reduces hypoxic cerebral vasodilation tendency).
• Dexamethasone (if rapid ascent unavoidable or for high-risk individuals).

Treatment

• Immediate descent: HACE is a neurological emergency. Descend immediately, even at night, even in bad weather. Delay is fatal.
• Supplemental oxygen (high flow).
• Dexamethasone: 8 mg loading dose (IM, IV, or oral), then 4 mg q6h. Reduces cerebral vasogenic edema. Most important pharmacological treatment.
• Portable hyperbaric bag (Gamow bag) if descent impossible.

SECTION D: BUBBLE FORMATION AND DECOMPRESSION SICKNESS (Objectives 9.13, 9.33–9.43)

Microscopic gas nuclei — preexisting tiny gas-filled spaces within tissues and at tissue interfaces — are the seeds from which clinically significant DCS bubbles grow. De novo bubble formation from a perfectly homogeneous supersaturated liquid would require supersaturation ratios of 100–1,400 atmospheres (far exceeding anything physiologically possible). Instead, gas nuclei provide the necessary surfaces and initial volume for bubble growth at physiological supersaturation levels.

• Sources of gas nuclei: Tribonucleation (transient negative pressure at articular surfaces during joint movement), microcavities at hydrophobic-hydrophilic tissue interfaces, and surfaces of circulating particles. Physical activity at altitude increases gas nuclei generation → increases DCS risk.
• Bubble growth from nuclei: Once a nucleus is present and tissue is supersaturated, dissolved gas (primarily nitrogen) diffuses from the supersaturated surroundings into the nucleus, expanding it. Growth continues as long as supersaturation persists.
• Silent bubbles (VGE): Doppler ultrasound studies have shown that venous gas emboli (VGE) are detectable in the circulation of many subjects following altitude or diving decompression WITHOUT clinical DCS. Bubbles = DCS is NOT always true — only when bubble burden exceeds the body’s capacity to eliminate them or when they cause mechanical/embolic injury does clinical DCS manifest.

John Scott Haldane (1860–1936) was commissioned by the British Admiralty to investigate safe decompression procedures for Royal Navy divers. His work, published in 1908, established the foundational principles of DCS prevention and decompression table design that underlie all modern decompression theory:

Modern limitations of Haldane’s theory: The single critical supersaturation ratio is too simplistic. Different tissues require different allowable ratios; current models use variable ratios dependent on tissue half-time and nitrogen content. Haldane’s tables were overly conservative for short dives and not safe enough for long dives. Nevertheless, his conceptual framework of tissue half-times and critical supersaturation ratios remains foundational.

The lungs serve as the primary filter for venous gas bubbles (VGE) in the circulation — they are remarkably efficient at trapping and eliminating small gas emboli before they can reach the systemic arterial circulation:

• Pulmonary capillary filtration: Small VGE that enter the pulmonary circulation are trapped in the pulmonary capillary bed. Gas from these trapped bubbles diffuses across the alveolar membrane into the alveolar gas and is exhaled. This is the primary elimination route for small bubbles.
• Exhalation of inert gas: As nitrogen diffuses from bubbles into the bloodstream and then across the alveolar membrane, it is exhaled in expired breath. Breathing 100% oxygen maximizes the nitrogen partial pressure gradient from bubble to alveolus, accelerating this elimination.
• Pulmonary filter overload: When the VGE burden overwhelms pulmonary filtration capacity (large bubble loads from severe DCS), bubbles bypass the pulmonary filter through: (a) transpulmonary passage (passage of bubbles directly through the pulmonary capillaries when their size is small enough or when pressure overwhelms the filter); (b) arteriovenous shunts in the lung (anatomical connections present in 5–10% of the population); or (c) PFO shunting (patent foramen ovale: bubbles cross from right to left atrium during Valsalva or elevated right atrial pressure). Bubbles that bypass the pulmonary filter become arterialized → arterial gas embolism (AGE).
• Progressive reduction: Successfully filtered VGE are progressively reduced in size by diffusion. Breathing 100% O₂ creates a ‘nitrogen window’ (zero inspired N₂) that maximizes the gradient driving bubble nitrogen elimination through this pathway.

The relationship between altitude (atmospheric pressure) and DCS incidence has been precisely characterized in controlled hypobaric chamber research:

• Below 7,500 ft (<2,287 m): No supersaturation occurs from sea-level nitrogen loading. DCS risk is zero from altitude alone.
• 7,500–13,000 ft (2,287–3,962 m): Supersaturation begins but is below the critical threshold for most tissues. DCS incidence is below 0.001% — essentially zero in practice.
• ~18,000–19,500 ft (~5,500 m): 5% DCS threshold. Approximately 5% of sea-level-saturated individuals develop DCS symptoms (zero prebreathe, mild exercise, 4-hour exposure). This is the lowest altitude of practical DCS concern for aviation medicine.
• ~23,000 ft (~7,010 m): 50% DCS incidence under zero prebreathe, mild exercise conditions. More than half of exposed individuals develop DCS symptoms.
• >25,000 ft: Very high DCS risk without oxygen prebreathe; even short exposures produce symptoms.
• Cabin pressurization to 8,000 ft: Supersaturation ratio R = 573/565 ≈ 1.01. Essentially zero DCS risk — explains why commercial aviation is safe from DCS.

• Altitude (primary): Higher altitude = greater supersaturation = higher DCS risk.
• Duration at altitude: Longer exposure allows slow tissues (fat, tendons) to develop increasing supersaturation.
• Exercise at altitude: ≈2× DCS risk vs. seated rest. Tribonucleation generates more gas nuclei; ↑ cardiac output delivers supersaturated blood to more tissues.
• Obesity: Increased adipose tissue volume (nitrogen solubility 5× higher in fat than plasma). Larger total nitrogen reservoir.
• Older age: ↑ adipose tissue; ↓ tissue perfusion (slower denitrogenation); more preexisting gas nuclei.
• Prior DCS history: May indicate lower individual threshold for bubble nucleation; increased recurrence risk.
• Patent foramen ovale (PFO): Allows venous bubbles to arterialized via right-to-left shunting (especially during Valsalva/AGSM). Present in ~27% of adults.
• Dehydration: ↓ plasma volume → impairs N₂ transport to lungs for elimination.
• Cold environment: ↑ nitrogen solubility; ↓ peripheral perfusion → slower denitrogenation.
• Recent scuba diving: Elevated tissue PN₂ above sea-level baseline. Mandatory surface interval required (UHMS: 12–24+ hours).
• Rapid rate of ascent: Faster ascent → faster supersaturation development before tissues can denitrogenate.
• Repetitive altitude exposures (same day): Cumulative bubble burden; sensitization of gas nuclei.

In altitude-induced (hypobaric) DCS, joint pain is by far the most common manifestation:

• Joint pain (‘bends’): Approximately 70–80% of all altitude DCS cases involve pain in or around a major joint. Shoulder is most frequently affected, followed by elbow, knee, hip, and wrist.
• Skin manifestations (pruritus, cutis marmorata): Approximately 5–10% of cases.
• Neurological DCS: Approximately 10–15% of altitude DCS cases (more common in altitude vs. diving DCS because of spinal cord white matter fat sheaths).
• Pulmonary DCS (chokes): Less than 4% of altitude DCS cases — rare but life-threatening.
• Vestibular DCS (staggers): Less than 5% of cases.

Table 9.8. Four Manifestations of Altitude DCS: Type, Symptoms, and Key Features

• Recognize symptoms: Joint pain, skin symptoms, visual changes, neurological symptoms (weakness, numbness, paresthesias, confusion, vertigo), respiratory symptoms (substernal pain, dyspnea) during or after altitude exposure = DCS until proven otherwise.
• Declare in-flight emergency and descend: Descend to lowest safe altitude as rapidly as possible. Boyle’s Law: increased pressure → reduced bubble volume. Most altitude DCS resolves with descent to ground level.
• Switch to 100% oxygen immediately: If not already on O₂. Benefits: maximizes N₂ elimination gradient from tissues and bubbles; oxygenates ischemic tissues around bubbles; prevents further nitrogen loading.
• Land at nearest airfield with capable medical support: Do not delay landing to return to home base.
• Continue 100% oxygen on ground for at least 2 hours: Allows continued N₂ elimination and bubble resolution.
• Evaluate with flight surgeon: Every DCS event requires formal evaluation regardless of apparent resolution. Do NOT administer analgesics — pain is the treatment response monitor.
• Transport to hyperbaric facility if indicated: Type I DCS not resolving within 30–60 min of surface O₂, OR any Type II symptoms at any time → emergency HBO therapy (USN Treatment Table 5 or 6).
• Document the event: Complete DCS incident report including altitude profile, prebreathe compliance, exercise history, symptom onset, character, treatment, and response.

Hyperbaric oxygen (HBO) therapy is the definitive treatment for DCS that fails to resolve with descent and surface-level oxygen. It works through multiple simultaneous mechanisms:

• Boyle’s Law (pressure compression): At 2.8 ATA (60 fsw, USN Treatment Table 6), bubble volume is reduced to approximately 36% of its sea-level volume. Mechanical compression partially or completely restores blood flow through vessels previously occluded by bubbles and reduces mechanical tissue stretching.
• Nitrogen elimination from bubbles (concentration gradient): At 2.8 ATA with 100% O₂ breathing, inspired P(N₂) = 0. The nitrogen partial pressure inside the bubble greatly exceeds the surrounding tissue nitrogen partial pressure (which is being cleared by 100% O₂). This gradient drives nitrogen out of the bubble into surrounding tissues and then to blood and lungs for elimination. Bubble nitrogen content decreases progressively.
• Oxygen window: When breathing 100% O₂ at elevated pressure, alveolar nitrogen pressure is zero while all other gases remain at normal partial pressures. This creates a large diffusion gradient (the ‘oxygen window’) driving all dissolved nitrogen from tissues and bubbles toward the alveoli for elimination. Maximized by 100% O₂ at pressure.
• Tissue oxygenation via hyperoxygenated plasma: At 2.8 ATA breathing 100% O₂, arterial PO₂ reaches approximately 1,900–2,000 mmHg. Plasma-dissolved O₂ (without hemoglobin) can perfuse areas of partial vascular obstruction where red cell-carrying blood cannot pass, breaking the cycle of hypoxia-induced edema and inflammation around bubble sites.
• Anti-inflammatory effects: HBO reduces neutrophil-mediated endothelial injury, platelet aggregation, and inflammatory mediator release triggered by bubble-blood contact, limiting secondary tissue damage.

SECTION E: TRAPPED GAS DISORDERS — EAR BLOCKS AND SINUS BLOCKS (Objectives 9.44–9.48)

An ear block (barotitis media, aerotitis media, otitic barotrauma) results from the failure of the Eustachian tube to equilibrate the pressure of the gas-filled middle ear cavity with changing ambient barometric pressure during altitude changes. Its cause is a tripartite interaction of physical (Boyle’s Law), anatomical, and physiological factors:

Physical (Boyle’s Law) Cause

The middle ear is a gas-filled cavity (~0.5–1.0 mL) enclosed by the tympanic membrane laterally and the ossicular chain medially. During ascent, ambient pressure falls → middle ear gas EXPANDS (Boyle’s Law) → middle ear pressure exceeds ambient → the excess pressure pushes the TM outward AND passively opens the Eustachian tube from within (middle ear is the high-pressure side), venting gas to the nasopharynx. Ascent equalization is passive and generally automatic.

During DESCENT, the reverse occurs: ambient pressure rises → middle ear gas is now at LOWER pressure than ambient → the differential pressure acts to push the TM inward AND to press the Eustachian tube’s pharyngeal opening closed (ambient pressure is now the high side). The middle ear cannot auto-vent during descent — active opening of the Eustachian tube is required.

Anatomical Causes

• Eustachian tube normally collapsed: The Eustachian tube is approximately 35–45 mm long; its medial (pharyngeal) two-thirds is fibrocartilaginous and normally collapsed at rest, kept closed by mucosal surface tension. It must be actively opened by tensor veli palatini contraction (during swallowing, yawning, or deliberate equalization maneuvers).
• Tube orientation: The tube runs inferomedially from the middle ear to the nasopharynx. This orientation means that during descent the increasing ambient pressure acts to compress the pharyngeal opening further, while the relatively lower middle ear pressure would tend to draw the tube walls together — opposing tube opening.
• Tube locking: When the pressure differential across the TM exceeds approximately 80–100 mmHg, the Eustachian tube is mechanically ‘locked’ — the mucosal surfaces are pressed together by ambient pressure and cannot be separated by voluntary maneuvers.

Physiological Causes

• Upper respiratory tract infection (URI): The most common precipitating factor. Mucosal inflammation and edema of the Eustachian tube orifice and tube walls reduce its caliber and increase resistance to opening.
• Allergic rhinitis: Chronic mucosal swelling from allergy impairs tube function. Seasonal exacerbations increase DCS risk for altitude flights.
• Anatomical variants: Narrow tubes, enlarged adenoids (children), or structural nasopharyngeal abnormalities can mechanically impede tube opening.
• Active closure reflex: Nasal congestion from any cause (decongestant rebound, sinusitis) prevents the tube from opening normally.

Ear block symptoms develop as the pressure differential across the TM progressively increases during descent. The Teed classification grades severity:

Table 9.9. Teed Classification of Barotitis Media / Ear Block Severity

Common symptom sequence: Pressure/fullness → tinnitus → pain (mild → severe) → hearing loss (conductive, from middle ear effusion) → vertigo (if the effusion or pressure differential distorts the round/oval window membranes). Symptoms may persist for hours to days after descent if effusion has developed.

Prevention of ear blocks requires ensuring that the Eustachian tube remains patent and that pressure equalization occurs continuously throughout the altitude change. During ascent, middle ear pressure exceeds ambient and passive venting usually occurs automatically. The preventive interventions for ascent focus on:

• Swallowing and yawning (passive): During ascent, gas naturally vents from the higher-pressure middle ear through the passively opened tube with each swallow or yawn. Swallowing activates the tensor veli palatini, and even a slight opening allows the excess middle ear pressure to escape.
• Avoid flying with URI or significant nasal congestion: Primary prevention. An obstructed tube on ascent rarely causes problems (passive venting is easy) but sets the stage for a severe descent block.
• Topical nasal decongestants before flight: Oxymetazoline (Afrin) or xylometazoline applied 30 minutes before flight reduces nasal mucosal edema and may temporarily improve Eustachian tube function. Note: This is a risk-reduction strategy, not a substitute for grounding when tube function is clearly compromised.
• Valsalva maneuver (if needed on ascent): Rarely needed on ascent since passive venting usually suffices. Technique: Pinch nose, close mouth, attempt to exhale forcefully. This raises nasopharyngeal pressure, forcing air through the Eustachian tube into the middle ear (useful if tube is already slightly blocked on ascent).
• Frenzel maneuver: Pinch nose, close mouth, and push the tongue up and back as if pronouncing a ‘K’ sound. The tongue acts as a piston pressurizing the nasopharynx. Preferred over Valsalva because it avoids cardiovascular risk (no Valsalva-type straining) and can be repeated frequently.
• Toynbee maneuver: Pinch nose and swallow. Swallowing opens the Eustachian tube while nose occlusion allows bidirectional equalization. Useful diagnostic maneuver to confirm tube patency.

A sinus block (barosinusitis) results from the failure of a paranasal sinus ostium to equalize pressure between the gas-filled sinus cavity and the ambient environment during altitude changes. The physical mechanism is directly analogous to barotitis media but affects the sinuses rather than the middle ear.

Physical (Boyle’s Law) Cause

The paranasal sinuses (frontal, maxillary, ethmoid, and sphenoid) are gas-filled cavities that communicate with the nasal cavity through small ostia. During ascent, sinus gas expands and typically vents passively through the ostia (if patent). During DESCENT, the increasing ambient pressure must be admitted through the ostia into the sinus. If the ostia are obstructed, the sinus develops a relative negative pressure → mucosal engorgement and hemorrhage → severe pain.

Anatomical Causes

• Small sinus ostia: The ostia are naturally small (2–3 mm diameter). Any mucosal swelling can completely obstruct them.
• Frontal sinus drainage anatomy: The frontal sinus drains through the fronto-nasal duct, which is narrow, tortuous, and particularly susceptible to obstruction. This explains why FRONTAL sinus barotrauma is the most common and most severe form — the drainage pathway is the most vulnerable.
• Anatomical variations: Septal deviations, turbinate hypertrophy, or concha bullosa can narrow the ostiomeatal complex (the common drainage channel for multiple sinuses), predisposing to obstruction.

Physiological Causes

• URI and sinusitis: The most common precipitants. Mucosal inflammation from viral URI or bacterial sinusitis produces edema that obliterates the ostia.
• Allergic rhinitis: Chronic mucosal swelling and polyp formation narrow the ostiomeatal complex.
• Nasal polyps: Benign polyps (frequently associated with allergy, aspirin sensitivity, or chronic sinusitis) can physically obstruct sinus drainage pathways.
• Mucosal cysts and sinusitis sequelae: Retention cysts, post-infectious mucosal thickening, or previous sinus surgery scarring can narrow ostia.

A sinus block is a medical emergency in the cockpit because it can be instantly and completely incapacitating, impairing flight safety. Management: